Chlamydia Inhibits Interferon γ-inducible Major Histocompatibility Complex Class II Expression by Degradation of Upstream Stimulatory Factor 1

By Guangming Zhong, Tao Fan, and Li Liu

From the Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba R3E 0W3, Canada

Summary

We report that chlamydiae, which are obligate intracellular bacterial pathogens, can inhibit interferon (IFN)-γ-inducible major histocompatibility complex (MHC) class II expression. However, the IFN-γ-induced IFN regulatory factor-1 (IRF-1) and intercellular adhesion molecule 1 (ICAM-1) expression is not affected, suggesting that chlamydia may selectively target the IFN-γ signaling pathways required for MHC class II expression. Chlamydial inhibition of MHC class II expression is correlated with degradation of upstream stimulatory factor (USF)-1, a constitutively and ubiquitously expressed transcription factor required for IFN-γ induction of class II transactivator (CIITA) but not of IRF-1 and ICAM-1. CIITA is an obligate mediator of IFN-γ-inducible MHC class II expression. Thus, diminished CIITA expression as a result of USF-1 degradation may account for the suppression of the IFN-γ-inducible MHC class II in chlamydia-infected cells. These results reveal a novel immune evasion strategy used by the intracellular bacterial pathogen chlamydia that improves our understanding of the molecular basis of pathogenesis.

Key words: interferon γ induction • major histocompatibility complex class II • chlamydia • upstream stimulatory factor 1 • protein degradation

Materials and Methods

Chlamydial Infection and IFN-γ Stimulation. The following human cell lines were used: MCF-7 (a mammary epithelium line, often occurs (22, 23). We have recently demonstrated that chlamydia possesses a strong antiapoptotic activity (24), which may allow chlamydiae to escape CD8+ T cell attack. However, CD4+ T cell-mediated immunity also plays very important roles in controlling many intracellular pathogen infections (25, 26). As viruses that suppress IFN-γ-inducible MHC class II expression on the infected cells can evade CD4+ T cell recognition (16), we hypothesize that chlamydia may have also evolved strategies for inhibiting IFN-γ induction of MHC class II, which may partially contribute to the persistent infection. To test this hypothesis, we evaluated the effect of chlamydial infection on IFN-γ-inducible MHC class II antigen expression. We have found that chlamydial infection can indeed suppress IFN-γ-inducible MHC class II expression by selective disruption of IFN-γ signaling pathways. We further demonstrated that a chlamydia-dependent proteasome-like activity is responsible for the chlamydial inhibitory effect. These observations reveal a novel immune evasion strategy used by the intracellular bacterial pathogen chlamydia.
provided by Dr. Arnold Greenberg of the Manitoba Cancer Foundation; MRC-5 (fibroblast; American Type Culture Collection [ATCC]); 2C4 (fibroblast; provided by Dr. George Stark of the Cleveland Clinic Foundation); and HeLa (cervical epithelium; ATCC). Cells were infected with Chlamydia trachomatis LGV2 strain at a multiplicity of infection (MOI) of 5 or as indicated and for 24 h or as indicated in individual experiments (24). Cells with or without infection were stimulated with human IFN-γ (Pharmingen) at 200 U/ml or as indicated for another 10 h (for reverse transcriptase [RT]-PCR analysis) or 20-24 h (for flow cytometry and Western blot analysis).

Flow Cytometry. Cell samples were stained with mouse anti-HLA-DR (α; L243; ATCC), mouse anti-human intercellular adhesion molecule (ICAM)-1 (HA58; Pharmingen), or normal mouse IgG (Zymed Labs., Inc.). Primary antibody binding was detected using goat anti-mouse IgG conjugated with FITC (Caltag Labs) and analyzed with a FACSCalibur™ equipped with CellQuest software (Becton Dickinson). Dead cells were excluded by propidium iodine staining.

Western Blot Assay. Western blot assay was carried out as we previously described (24). Rabbit antibodies were used to detect IFN-γR (SC-700; Santa Cruz Biotechnology), tyrosine-phosphorylated signal transducers and activators of transcription (STAT)1α (91715; New England Biolabs, Inc.), IFN regulatory factor (IRF)-1 (SC-497), upstream stimulatory factor (USF)-1 (SC-464; Santa Cruz Biotechnology), HLA-DR α (DA6.147; provided by Dr. Peter Cresswell, Yale University; reference 27), and a chlamydial major outer membrane protein (MOMP; clone MC22, our unpublished data). Primary antibody binding was detected with horseradish peroxidase-conjugated goat anti-mouse IgG or -rabbit IgG, depending on the source of the primary antibodies, and visualized using an ECL kit (Amersham Corp.).

RT-PCR Assay. Cell samples were collected for RNA extraction using the Rneasy Mini Kit from QIAGEN, Inc. 2 μg of total RNA was used for each cDNA synthesis with random primers and the 1st Strand cDNA synthesis kit from Boehringer Mannheim. Aliquots of the cDNA samples were used as a template for amplifying specific gene fragments by PCR reactions (28, 29). The primers used for amplification of DR α (18), DM α (29), invariant chain p41 (IP41) (29), and IRF-1 (18) were previously described. The other primers used in this study were: for class II transactivator (CITA) amplification, 5′-GACAGGGTGGCCTGTTGGAGTC-3′ (forward) and 5′-GCGACCTGTAATTTGTGCTGTTG-3′ (reverse); for USF-1 amplification, 5′-TGGCACTGGTCAATTCTTTGTG (forward) and 5′-CTC-CTTCCTTCTTCTTCTTCTT-3′ (reverse); for inducible 2,3-dioxygenase (IDO) gene amplification, 5′-ATGCAATTCCGAGTGCCATTGCAT-3′ (forward) and 5′-GGTCTCCTCCGCCGAGCGCACT-3′ (reverse); and for β-actin amplification, 5′-ATGCAATTCCGAGTGCCATTGCAT-3′ (forward) and 5′-GGTCTCCTCCGCCGAGCGCACT-3′ (reverse); for β-actin mRNA detection was used as an internal control for the amount of cDNA synthesized. To ensure the specificity of the mRNA detection, all primers were designed to cover at least two exons, and parallel samples without RT were run as negative controls. The amplified DNA products were run on an agarose gel and visualized with ethidium bromide staining.

Results

Chlamydial Infection Inhibits IFN-γ-inducible MHC Class II Gene Expression. To investigate whether chlamydia possesses the ability to evade the IFN-γ-induced immune recognition mechanism, we evaluated IFN-γ-inducible MHC class II antigen expression in cells with or without chlamydial infection. IFN-γ significantly upregulated HLA-DR surface expression on uninfected cells, whereas the chlamydia-infected cells displayed a minimal level of DR, regardless of IFN-γ exposure (Fig. 1 A). However, chlamydial infection did not affect the IFN-γ-induced ICAM-1 surface expression (Fig. 1 A). These observations suggest that chlamydia selectively inhibits IFN-γ-inducible DR expression rather than preventing all IFN-γ-dependent signaling or generally suppressing surface protein expression. Furthermore, the total cellular protein level of IFN-γ-induced HLA-DR α was also significantly diminished in chlamydia-infected cells.
as compared with uninfected cells (Fig. 1 B), suggesting that the suppression of surface expression of HLA-DR was not due to an alteration in intracellular trafficking. The chlamydial inhibition of IFN-γ-induced HLA-DRα was reproduced in many other human cell lines, including HeLa, MRC-5, and 2C4 (Fig. 1 B), demonstrating that the inhibitory effect is not a cell line–specific phenomenon. To determine whether the chlamydial inhibition of HLA-DR expression occurs at the transcription or translation level, MHC class II mRNA levels were evaluated by semiquantitative RT-PCR. IFN-γ dramatically induced the expression of DRα, DMα, and Ip41 mRNA in the uninfected but not the infected cells (Fig. 1 C), suggesting that chlamydial inhibition of MHC class II occurred at the transcription level. Because the genes encoding the MHC class II presentation–related molecules DRα, DMα, and Ip41 share similar promoter structures and CIITA is a master regulator for the expression of these genes (30), we hypothesize that chlamydia may inhibit CIITA function or CIITA gene expression.

IFN-γ-inducible CIITA Expression Is Inhibited in Chlamydia-infected Cells. Although CIITA is constitutively expressed in professional APCs, such as dendritic cells and B cells, IFN-γ stimulation is often required for the expression of CIITA in nonprofessional APCs, such as epithelial cells (31). CIITA mRNA expression was induced by IFN-γ in uninfected MCF-7 cells (Fig. 2 A). However, CIITA mRNA expression was significantly lower in chlamydia-infected and IFN-γ-treated cells (Fig. 2 A), in accord with chlamydial inhibition of MHC class II gene expression. To investigate how CIITA gene expression was inhibited, we measured mRNA levels for three transcription factors, USF-1, STAT1, and IRF-1, all of which are required for IFN-γ-inducible transcription of the CIITA gene (32). Both USF-1 and STAT1 mRNAs were constitutively expressed, and IRF-1 mRNA was induced by IFN-γ in MCF-7 cells regardless of chlamydia infection (Fig. 2 A), suggesting that chlamydial infection did not affect transcription of the genes for these nuclear factors. Because the three transcription factors are considered to be sufficient and necessary for the IFN-γ induction of CIITA (32), we evaluated the protein levels of these transcription factors as well as upstream molecules in the IFN-γ signaling pathway. We found that IFN-γ, JAK-1, and STAT1 protein levels were not altered by chlamydial infection (Fig. 2 B). Chlamydia did not affect IFN-γ-induced STAT1 tyrosine phosphorylation (Fig. 2 B). Furthermore, IFN-γ induced both IRF-1 and ICAM-1 expression in chlamydia-infected cells (Figs. 1 A and 2 B). As STAT1 is required for the expression of both IRF-1 and ICAM-1 genes (32, 33), we conclude that STAT1 is transcriptionally functional in chlamydia-infected cells. The IFN-γ–induced IRF-1 in chlamydia-infected cells may also be transcriptionally functional, as we found that IFN-γ–induced expression of IDO gene in chlamydia-infected cells (data not shown), and it is known that IRF-1 is required for IFN-γ induction of IDO (34). Therefore, the failure of the IFN-γ-inducible CIITA expression in chlamydia-infected cells is likely due to the deficiency in USF-1. We found that the USF-1 protein was not detectable in chlamydia-infected cells (Fig. 2 B), despite normal USF-1 mRNA expression (Fig. 2 A). We next determined the cause of the USF-1 protein loss.

USF-1 is degraded by a proteasome-like activity in chlamydia-infected cells. Because USF-1 mRNA is expressed in chlamydia-infected cells with or without IFN-γ stimulation, the lack of USF-1 protein may be due to either the inhibition of translation of USF-1 mRNA or the accelerated degradation of USF-1 protein. We tested the protein degradation hypothesis by using protease inhibitors. We found that the proteasome inhibitor lactacystin prevented USF-1 protein degradation in chlamydia-infected cells (Fig. 2 C). Furthermore, the lactacystin treatment also preserved the IFN-γ–inducible HLA-DR expression in chlamydia-infected cells.

**Figure 2.** Chlamydial infection disrupts IFN-γ intracellular signaling pathways. (A) Chlamydial infection suppresses both HLA-DRα and CIITA but not IRF-1, STAT1α, or USF-1 mRNA expression in MCF-7 cells. The mRNA levels were analyzed by RT-PCR as described in Materials and Methods. (B) USF-1 protein is not detected in chlamydia-infected MCF-7 cells. The protein levels of IFN-γR, JAK-1, STAT1α, tyrosine-phosphorylated STAT1α, IRF-1, and USF-1 were detected using a Western blot assay. (C) Lactacystin prevents USF-1 degradation and preserves HLA-DRα expression in chlamydia-infected MCF-7 cells 10 h before IFN-γ stimulation, a chlamydia-infected cell sample was treated with lactacystin (Calbiochem) at a final concentration of 75 μM or with an equivalent amount of solvent DMSO and kept in culture during IFN-γ stimulation. HLA-DRα and USF-1 were detected in a Western blot assay. ns, nonspecific binding.

Zhong et al. 1993
and USF-1 degradation was also analyzed (Fig. 3B). The time course relationship between chlamydial growth was not degraded, regardless of the infection dose (Fig. 3A). This effect was selective, as USF-2 chlamydial protein was produced and less USF-1 protein organisms versus number of host cells) increased, more chlamydial protein was produced and less USF-1 protein was detected (Fig. 3A). The role of chlamydia and host protein synthesis, we first evaluated the relationship between the chlamydial infection dose and USF-1 degradation. As MOI (ratio of number of organisms versus number of host cells) increased, more chlamydial synthesis and inhibition of HLA-DR expression. To examine whether the USF-1 protein degradation in chlamydia-infected cells is dependent on chlamydial growth and protein synthesis, we first evaluated the relationship between the chlamydial infection dose and USF-1 degradation. As MOI (ratio of number of organisms versus number of host cells) increased, more chlamydial protein was produced and less USF-1 protein was detected (Fig. 3A). The effect was selective, as USF-2 was not degraded, regardless of the infection dose (Fig. 3A). The time course relationship between chlamydial growth and USF-1 degradation was also analyzed (Fig. 3B). Al-

Figure 3. Chlamydial protein synthesis is required for both USF-1 degradation and inhibition of HLA-DRα expression. (A) Correlation between infection dose and USF-1 degradation. 24 h after chlamydial infection at various MOI, MCF-7 cells were analyzed for chlamydial MOMP and host USF-1 and USF-2 protein levels in a Western blot assay. As the USF-2 protein level was not altered by chlamydial infection, it served as an internal control. (B) Time course relationship between chlamydial growth and USF-1 degradation. At various time points after infection, MCF-7 cells were lysed for the detection of USF-1, STAT1α, and MOMP in a Western blot assay. (C) Inhibition of chlamydial but not host protein synthesis prevents USF-1 degradation and preserves HLA-DRα expression. Rifampin (RF; final concentration, 0.1 μg/ml), chloramphenicol (CH; 60 μg/ml), and penicillin (PG; 100 μg/ml) were added at the beginning of chlamydial infection and maintained throughout the culture. Cycloheximide (CY; 10 μg/ml) was added to the culture 10 h before IFN-γ treatment and maintained during the IFN-γ stimulation. The MCF-7 cells were analyzed for protein levels of HLA-DRα, USF-1, USF-2, and chlamydial MOMP in a Western blot assay.

Discussion
We have demonstrated that the obligate intracellular bacterial pathogen chlamydia can inhibit IFN-γ-inducible MHC class II expression. This inhibitory effect has also been found with other intracellular pathogens, including leishmania (13), listeria (14), cowdria (15), and cytomegalovirus (16–18). CD4+ T cell-mediated immunity plays an important role in host defense against various intracellular infections (36–38). Recognition of the infected cells by CD4+ T cells often requires IFN-γ-inducible MHC class II expression in infected cells (36–38). However, mechanisms of IFN-γ–inducible MHC class II expression may represent an efficient immune evasion strategy used by intracellular pathogens to escape host defenses. Thus, chlamydial inhibition of IFN-γ-inducible MHC class II may contribute to the persistent infection caused by chlamydia in humans (22).

It has been demonstrated that cytomegalovirus can prevent IFN-γ–inducible class II expression in infected cells by both IFN-β–mediated inhibition (17, 39) and disruption of IFN-γ intracellular signaling pathways (16, 18). However, mechanisms of IFN-γ–inducible MHC class II inhibition by many other intracellular pathogens are still not clear (13–15). It was recently proposed that chlamydia...
Figure 4. Model for chlamydial inhibition of IFN-γ-inducible MHC class II expression. IFN-γ binding activates intracellular JAK/STAT pathways. USF-1 is a constitutively and ubiquitously expressed downstream transcription factor required for IFN-γ-inducible CIITA expression. Chlamydial infection degrades USF-1, which results in diminished expression of CIITA in chlamydia-infected cells. As CIITA is an obligate mediator for transcription of MHC class II genes, chlamydial degradation of USF-1 finally leads to suppression of IFN-γ-inducible MHC class II. However, because the upstream pathways of IFN-γ signaling are still intact in chlamydia-infected cells, expression of IRF-1, ICAM-1, and IDO is not affected by chlamydia infection.

may suppress IFN-γ-inducible MHC class II expression by stimulating host cells to release IFN-β (40). Here we show that the intracellular bacterial pathogen chlamydia has evolved a more specific mechanism for disrupting IFN-γ signaling pathways and inhibiting MHC class II expression. Chlamydia degrades USF-1, a downstream transcription factor required for IFN-γ-inducible MHC class II but not IRF-1 and ICAM-1 expression (Fig. 4). USF-1 degradation may represent an efficient means of interrupting IFN-γ-inducible MHC class II expression by chlamydia. Although the constitutively and ubiquitously expressed USF-1 is a member of the basic helix-loop-helix family consisting of multiple transcription factors, including Myc and USF-2, only USF-1 is both necessary and sufficient for binding to the E box within the CIITA promoter IV and cooperating with STAT1 and IRF-1 for promoting transcription of CIITA (32). Therefore, the constitutively and ubiquitously expressed USF-1 may serve as a convenient and efficient target for chlamydia-induced degradation. The correlation between the degradation of USF-1 and the suppression of IFN-γ-inducible MHC class II further confirms that USF-1 plays a critical role in IFN-γ induction of MHC class II (32). Besides its involvement in MHC class II expression, USF-1 also participates in many other cellular activities, including promoting the transcription of fatty acid synthase in response to insulin regulation (41), interfering with Ras transformation (42), and transactivating the promoter of the p53 tumor suppressor gene (43). Depletion of USF-1 may cause inhibition of host cell lipid biosynthesis and promotion of host cell survival, both of which are likely beneficial to the intracellular chlamydia organisms.

Proteolysis is an important aspect of normal cellular physiology (44–46). Many viruses can take advantage of host proteolysis for the purposes of evading host defenses (2, 47). For example, human cytomegalovirus infection can induce degradation of JAK-1, a critical upstream kinase required for IFN-γ JAK/STAT signaling pathways, to suppress IFN-γ-inducible MHC class II on the infected cells (18). Furthermore, the cytomegalovirus-induced degradation can be inhibited by the proteasome inhibitor Z-L3VS (18, 48), suggesting that cytomegalovirus may be able to manipulate host proteasome activity. Because USF-1 degradation by chlamydia is inhibited by lactacystin and lactacystin is a potent proteasome inhibitor (48, 49), we propose that chlamydia may also produce a factor(s) for manipulating host proteasomes. Efforts to identify the chlamydial factor(s) are underway.

We thank Dr. Ronald N. Germain for helpful discussions and critically reading the manuscript and Drs. Peter Cresswell, George Stark, and Arnold Greenberg for providing useful reagents for this work.

This work was supported by the Medical Research Council (MRC) of Canada. G. Zhong is the recipient of an MRC scholarship.

Address correspondence to Guangming Zhong, Dept. of Medical Microbiology, University of Manitoba, 508-730 William Ave., Winnipeg, Manitoba, Canada R3E 0W3. Phone: 204-789-3835; Fax: 204-789-3926; E-mail: gmzhong@cc.umanitoba.ca

Received for publication 16 February 1999 and in revised form 30 April 1999.

References
1. Germain, R.N. 1994. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell. 76:287–299.
2. Ploegh, H.L. 1998. Viral strategies of immune evasion. Science. 280:248–253.
3. Ahn, K., A. Gruhler, B. Galocha, T.R. Jones, E.J. Wiertz, H.L. Ploegh, P.A. Peterson, Y. Yang, and K. Fruh. 1997. The ER-luminal domain of the HCMV glycoprotein US6
inhibits peptide translocation by TAP. Immunity. 6:613–621.
4. Hengel, H., T. Flohr, G.J. Hammerling, U.H. Kozinskiowski, and F. Momburg. 1996. Human cytomegalovirus inhibits peptide translocation into the endoplasmic reticulum for MHC class I assembly. J. Gen. Virol. 77:2287–2296.
5. Lehner, P.J., J.T. Kurtzunne, G.W. Wilkinson, and P. Cresswell. 1997. The human cytomegalovirus US5 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation. Proc. Natl. Acad. Sci. USA. 94:6904–6909.
6. Jones, T.R., and L. Sun. 1997. Human cytomegalovirus US2 destabilizes major histocompatibility complex class I heavy chains. J. Virol. 71:2970–2979.
7. Jones, T.R., E.J. Wiertz, L. Sun, K.N. Fish, J.A. Nelson, and H.L. Ploegh. 1996. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc. Natl. Acad. Sci. USA. 93:11327–11333.
8. Maelhold, R.P., E.J. Wiertz, T.R. Jones, and H.L. Ploegh. 1997. The HCMV gene products US11 and US2 differ in their ability to attack allelic forms of murine major histocompatibility complex (MHC) class I heavy chains. J. Exp. Med. 185:363–366.
9. Schust, D.J., D. Tortorella, J. Seebach, C. Phan, and H.L. Ploegh. 1996. Trophoblast class I major histocompatibility complex (MHC) products are resistant to rapid degradation imposed by the human cytomegalovirus (HCMV) gene products US2 and US11. J. Exp. Med. 188:497–503.
10. Wiertz, E.J., T.R. Jones, L. Sun, M. Bogyo, H.J. Geuze, and H.L. Ploegh. 1996. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell. 84:769–779.
11. Hughes, E.A., C. Hammond, and P. Cresswell. 1997. Misfolded major histocompatibility complex class I heavy chains are translocated into the cytoplasm and degraded by the proteasome. Proc. Natl. Acad. Sci. USA. 94:1896–1901.
12. Collins, K.L., B.K. Chen, S.A. Kalams, B.D. Walker, and D. Baltimore. 1998. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature. 391:397–401.
13. Reiner, N.E., W. Ng, T. M a, and W.R. M c a r. 1998. Kinetics of gamma interferon binding and induction of major histocompatibility complex class II mRN A in Leishmania-infected macrophages. Proc. Natl. Acad. Sci. USA. 85:4330–4334.
14. Schuller, S., B. Kugler, and W. Goebel. 1998. Suppression of major histocompatibility complex class I and class II gene expression in Listeria monocytogenes-infected murine macrophages. FEBS Lett. Immuno. 361:209–299.
15. Vachieri, N., I. Trap, P. Totte, D. M a r t i n e, and A. Bensaid. 1998. Inhibition of MHC class I and II class II cell surface expression on bovine endothelial cells upon infection with Chlamydia trachomatis. V. Nat. Immuno. 361:37–48.
16. H e i s e, M.T., M. Connick, and H.W.T. Virgin. 1998. Murine cytomegalovirus inactivates IFN-γ-induced MHC class II expression on macrophages: the role of type I interferon. Virol. 241:331–344.
17. H e i s e, M.T., J.L. Pollock, A. O’Guin, M.L. Borkon, S. Bormley, and H.W.T. Virgin. 1998. Murine cytomegalovirus infection inhibits IFN-γ-induced MHC class II expression on macrophages: the role of type I interferon. Virol. 241:331–344.
18. Miller, D.M., B.M. R a h i l l, J.M. B o s s, M.D. L a r m o r e, J.E. Durbin, J.W. Waldman, and D.D. Sedmak. 1998. Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of Jak/Stat pathway. J. Exp. Med. 187:675–683.
19. Moulder, J.W. 1991. Interaction of chlamydiae and host cells in vitro. Microbiol. Rev. 55:143–190.
20. Grayston, J.T., C.C. Kuo, L.A. Campbell, S.P. W ang, and L.A. Jackson. 1997. Chlamydia pneumoniae and cardiovascular disease. Cardiologia. 42:1145–1151.
21. Grayston, J.T., and S. W ang. 1975. New knowledge of chlamydiae and the diseases they cause. J. Infec. Dis. 132:87–105.
22. Beatty, W.L., R.P. M a r i o t s o n, and G.I. Byrne. 1994. Persistent chlamydiae: cell culture to a paradigm for chlamydial pathogenesis. Microbiol. Rev. 58:686–699.
23. Holland, M.J., R.L. Bailey, D.J. Conway, F. Culley, G. Miranpuri, G.I. Byrne, H.C. Whittle, and D.C. M abey. 1996. T helper type-1 (Th1)/Th2 profiles of peripheral blood mononuclear cells (PBMC): responses to antigens of Chlamydia trachomatis in subjects with severe trachomatous scarring. Clin. Exp. Immunol. 105:429–435.
24. Fan, T., H. Lu, H. Hu, L. Shi, G.A. M c l a r t y, D.M. N a nce, A.H. Greenberg, and G. Zhong. 1998. Inhibition of apoptosis in chlamydia-infected cells: blockade of mitochondrial cytochrome c release and caspase activation. J. Exp. Med. 187:487–496.
25. Geginat, G., M. L a l i c, M. K r e t s c h m a r, W. Goebel, H. Hof, S. Palm, and A. B ub e r t. 1998. Th1 cells specific for a secreted protein of Listeria monocytogenes are protective in vivo. J. Immunol. 160:6046–6055.
26. Perry, L.L., K. F e l i z e r, and H.D. C al dw ell. 1997. Immunity to Chlamydia trachomatis is mediated by T helper 1 cells through IFN-γ-dependent and -independent pathways. J. Immunol. 158:3344–3352.
27. Arunachalam, B., M. P a n, and P. Cresswell. 1998. Intracellular formation and cell surface expression of a complex of an intact lyososomal protein and MHC class II molecules. J. Immunol. 160:5797–5806.
28. Chang, C.H., J.D. Fontes, M. Peterlin, and R.A. Flavell. 1994. Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes. J. Exp. Med. 180:1367–1374.
29. Albanesi, C., A. Cavani, and G. Girolomoni. 1998. Interferon-γ-stimulated human keratinocytes express the genes necessary for the production of peptide-loaded MHC class II molecules. J. Invest. Dermatol. 110:138–142.
30. Mach, B., V. Steinme, E. M artine-Soria, and W. R e ith. 1996. Regulation of MHC class II genes lessons from a disease. Annu. Rev. Immunol. 14:301–331.
31. M di l e h t h a l - M o tt e t, A., L.A. O t t e n, V. Steinme, and B. M ach. 1997. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO (Eur. Mol. Biol. Organ.) J. 16:2851–2860.
32. M l e h t h a l - M o tt e t, A., W. Di Berardino, L.A. O t t e n, and B. M ach. 1998. Activation of the MHC class II transactivator CIITA by interferon-γ requires cooperative interaction between Stat1 and USF-1. Immunity. 8:157–166.
33. W al t e r, M.J., D.C. L ook, R.M. T id w e ll, W.T. R o w i t, and M.J. H o lztzman. 1997. Targeted inhibition of interferon-γ-dependent intercellular adhesion molecule-1 (ICAM-1) expression using dominant-negative Stat1. J. Biol. Chem. 272:
34. Chon, S.Y., H.H. Hassanain, R. Pine, and S.L. Gupta. 1995. Involvement of two regulatory elements in interferon-gamma-regulated expression of human indoleamine 2,3-dioxygenase gene. J. Interferon Cytokine Res. 15:517–526.
35. Barbour, A.G., K. Amano, T. Hackstadt, L. Perry, and H.D. Caldwell. 1982. Chlamydia trachomatis has penicillin-binding proteins but not detectable muramic acid. J. Bacteriol. 151:420–428.
36. Rakhmilevich, A.L. 1994. Evidence for a significant role of CD4+ T cells in adoptive immunity to Listeria monocytogenes in the liver. Immunology. 82:249–254.
37. Kaufmann, S.H. 1993. Immunity to intracellular bacteria. Annu. Rev. Immunol. 11:129–163.
38. Su, H., R. Messer, W. Whitmire, E. Fischer, J.C. Portis, and H.D. Caldwell. 1998. Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable Chlamydiae. J. Exp. Med. 188:809–818.
39. Sedmak, D.D., S. Chaiwiriyakul, D.A. Knight, and W.J. Waldmann. 1995. The role of interferon β in human cytomegalovirus-mediated inhibition of HLA DR induction on endothelial cells. Arch. Virol. 140:111–126.
40. Rodel, J., A. Groh, H. Vogelsang, M. Lehmann, M. Hartmann, and E. Straube. 1998. Beta interferon is produced by Chlamydia trachomatis-infected fibroblast-like synoviocytes and inhibits gamma interferon-induced HLA-DR expression. Infec. Immun. 66:4491–4495.
41. Wang, D. and S.H. Sul. 1997. Upstream stimulatory factor binding to the E-box at −65 is required for insulin regulation of the fatty acid synthase promoter. J. Biol. Chem. 272:26367–26374.
42. Aperlo, C., E.K. Boulukos, and P. Pognonec. 1996. The basic region/helix-loop-helix/leucine repeat transcription factor USF interferes with Ras transformation. Eur. J. Biochem. 241:249–253.
43. Reisman, D. and V. Rotter. 1993. The helix-loop-helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene. Nucleic Acids Res. 21:345–350.
44. Lupas, A., J.M. Flanagan, T. Tamura, and W. Baumeister. 1997. Self-compartmentalizing proteases. Trends Biochem. Sci. 22:399–404.
45. Glas, R., M. Bogyo, J.S. McMaster, M. Gaczynska, and H.L. Ploegh. 1998. A proteolytic system that compensates for loss of proteasome function. Nature. 392:618–622.
46. Gottesman, S., M. Maurizi, and S. Wickner. 1993. The helix-loop-helix-containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene. Nucleic Acids Res. 21:345–350.
47. Ploegh, H.L. 1997. Destruction of proteins as a creative force. Immunol. Today. 18:269–271.
48. Bogyo, M., S. Shin, J.S. McMaster, and H.L. Ploegh. 1998. Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes. Chem. Biol. 5:307–320.
49. Groll, M., L. Ditzel, J. Low, D. Stock, M. Bochtler, H.D. Bartunik, and R. Huber. 1997. Structure of 20S proteasome from yeast at 2.4 Å resolution. Nature. 386:463–471.